InflaRx N.V. (IFRX) - 5i Research

InflaRx N.V. (IFRX $0.86)
- $0.86 Cap: $50M
- View IFRX Profile
- View Questions on IFRX

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

InflaRx N.V. (IFRX $0.86)
- $0.86 Cap: $50M
- View IFRX Profile
- View Questions on IFRX

Q: Can you please provide your expert insights into these two companies from investment perspective.
IFRX dropped 90% due to a failed Phase 2 and has roughly more money than its current market cap plus some other drug candidates in the pipeline. Do you think there is potential at the current price?
MYT dropped from more than 2 dollars to 66 cents, with a recent financing at 1.65 cents about two weeks ago. I tried to dig into their quarterly financials, but could not find them. What do you think about it? Where can I find their quarterly financials?

Read Answer Asked by Imtiaz on June 10, 2019